Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy


About this study

This is a Phase 1 study designed to test the tolerability and feasibility of intravesical therapy with an attenuated Measles virus (MV-NIS) in patients with urothelial carcinoma who are undergoing radical cystectomy but are ineligible or do not desire neoadjuvant chemotherapy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥ 18 years.
  • Diagnosis of UC of the bladder, with:
    • histologic confirmation of the primary UC pathology;
    • indication for RC;
    • ineligibility for platinum-based neoadjuvant chemotherapy. This may be due to (i) patients not being indicated for neoadjuvant chemotherapy due to noninvasive disease; (ii) not eligible for neoadjuvant chemotherapy due to safety concerns, contraindications, or comorbidities OR (iii) patients refused neoadjuvant chemotherapy.
  • ECOG Performance Status (PS) 0 or 1.
  • Ability to provide informed consent.
  • Willingness to comply with all required protocol procedures including providing biologic specimens and returning to the clinical study site for follow up visits.
  • Performance status sufficient to undergo RC (in the opinion of the enrolling urologist).
  • The following laboratory values obtained ≤ 14 days prior to study day 1:
    • ANC ≥ 1500/mm^3;
    • Platelets ≥ 100,000/mm^3;
    • HgB > 9.0 g/dL;
    • Total bilirubin ≤ institutional upper limit of normal (ULN);
    • SGOT (AST) ≤ 1.5 x ULN;
    • Creatinine clearance ≥ 30 ml/min.
  • Must be willing to implement contraception throughout the study and for 8 weeks after intravesical administration of MV-NIS.

Exclusion Criteria:

  • Variant UC pathology (defined as > 25% variant histology in the diagnostic bladder biopsy), including but not limited to micropapillary, signet ring, sarcomatoid, UC with squamous differentiation and clear cell variants.
  • Patients with any other prior malignancy are not allowed except for the following:
    • History of or concurrent non-invasive UC involving a portion of urinary tract outside of the bladder;
    • Adequately treated basal cell or squamous cell skin cancer;
    • In situ cervical cancer;
    • Adequately treated Stage I or II cancer from which the patient is currently in complete remission or other cancer from which the patient has been disease-free for 2 years.
  • Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.
  • Any of the following prior therapies:
    • Chemotherapy ≤ 3 weeks prior to study day 1;
    • Biologic therapy ≤ 4 weeks prior to study day 1;
    • Radiation therapy ≤ 3 weeks prior to study day 1;
    • Investigational therapy ≤ 4 weeks prior to study day 1.
  • Failure to fully recover from acute, reversible effects defined as ≤ grade 1 CTCAE v.4.03 of prior systemic therapy regardless of interval since last treatment.
  • Other concurrent investigational therapy (utilized for a non-FDA-approved indication and in the context of a research investigation).
  • Any of the following because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects:
    • Pregnant women;
    • Nursing women;
    • Men or women of childbearing potential who are unwilling to employ adequate contraception during treatment and 8 weeks after intravesical administration of MV-NIS.
  • Patients with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immuno-suppressive medications within 14 days of study drug administration. Inhaled or topical steroids, and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
  • History of organ transplantation.
  • Requiring blood product support.
  • Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV RNA), or human immunodeficiency virus (HIV1 or 2) indicating acute or chronic infection.
  • Active infection (any grade) ≤ 5 days prior to study day 1.
  • Active TB infection.
  • Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
  • Current exposure to household contacts ≤ 15 months old or household contact with known immunodeficiency.
  • Unwillingness to avoid household contacts ≤ 15 months old or household contact with known immunodeficiency 1 week after treatment.
  • Allergy to measles vaccine or history of severe reaction to prior measles vaccination.
  • Allergy to iodine.
    • Note: This does not include reactions to intravenous contrast materials.



Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Bradley Leibovich, M.D.

Contact us for the latest status

Contact information:

Tessa Kroeninger CCRP


Jacksonville, Fla.

Mayo Clinic principal investigator

Paul Young, M.D.

Closed for enrollment

Contact information:

Miriam Green


More information


Publications are currently not available

Mayo Clinic Footer